These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 20388407)
21. Cripto-1: an embryonic gene that promotes tumorigenesis. de Castro NP; Rangel MC; Nagaoka T; Salomon DS; Bianco C Future Oncol; 2010 Jul; 6(7):1127-42. PubMed ID: 20624125 [TBL] [Abstract][Full Text] [Related]
22. Identification of Cripto-1 in human milk. Bianco C; Wechselberger C; Ebert A; Khan NI; Sun Y; Salomon DS Breast Cancer Res Treat; 2001 Mar; 66(1):1-7. PubMed ID: 11368405 [TBL] [Abstract][Full Text] [Related]
23. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Minchiotti G; Parisi S; Liguori G; Signore M; Lania G; Adamson ED; Lago CT; Persico MG Mech Dev; 2000 Feb; 90(2):133-42. PubMed ID: 10640699 [TBL] [Abstract][Full Text] [Related]
24. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Strizzi L; Abbott DE; Salomon DS; Hendrix MJ Cell Cycle; 2008 Jul; 7(13):1931-5. PubMed ID: 18604175 [TBL] [Abstract][Full Text] [Related]
25. Nodal/Cripto signaling in fetal male germ cell development: implications for testicular germ cell tumors. Spiller CM; Bowles J; Koopman P Int J Dev Biol; 2013; 57(2-4):211-9. PubMed ID: 23784832 [TBL] [Abstract][Full Text] [Related]
26. Non-cell-autonomous role for Cripto in axial midline formation during vertebrate embryogenesis. Chu J; Ding J; Jeays-Ward K; Price SM; Placzek M; Shen MM Development; 2005 Dec; 132(24):5539-51. PubMed ID: 16291788 [TBL] [Abstract][Full Text] [Related]
27. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Raff AB; Gray A; Kast WM Cancer Lett; 2009 May; 277(2):126-32. PubMed ID: 18838214 [TBL] [Abstract][Full Text] [Related]
29. Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. Williams TA; Monticone S; Morello F; Liew CC; Mengozzi G; Pilon C; Asioli S; Sapino A; Veglio F; Mulatero P Hypertension; 2010 Jun; 55(6):1468-75. PubMed ID: 20385969 [TBL] [Abstract][Full Text] [Related]
30. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Bianco C; Strizzi L; Rehman A; Normanno N; Wechselberger C; Sun Y; Khan N; Hirota M; Adkins H; Williams K; Margolis RU; Sanicola M; Salomon DS Cancer Res; 2003 Mar; 63(6):1192-7. PubMed ID: 12649175 [TBL] [Abstract][Full Text] [Related]
31. Cripto-independent Nodal signaling promotes positioning of the A-P axis in the early mouse embryo. Liguori GL; Borges AC; D'Andrea D; Liguoro A; Gonçalves L; Salgueiro AM; Persico MG; Belo JA Dev Biol; 2008 Mar; 315(2):280-9. PubMed ID: 18241853 [TBL] [Abstract][Full Text] [Related]
32. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Gong YP; Yarrow PM; Carmalt HL; Kwun SY; Kennedy CW; Lin BP; Xing PX; Gillett DJ Eur J Surg Oncol; 2007 May; 33(4):438-43. PubMed ID: 17125961 [TBL] [Abstract][Full Text] [Related]
33. Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. Watanabe K; Bianco C; Strizzi L; Hamada S; Mancino M; Bailly V; Mo W; Wen D; Miatkowski K; Gonzales M; Sanicola M; Seno M; Salomon DS J Biol Chem; 2007 Oct; 282(43):31643-55. PubMed ID: 17720976 [TBL] [Abstract][Full Text] [Related]
34. Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Sun Y; Strizzi L; Raafat A; Hirota M; Bianco C; Feigenbaum L; Kenney N; Wechselberger C; Callahan R; Salomon DS Am J Pathol; 2005 Aug; 167(2):585-97. PubMed ID: 16049342 [TBL] [Abstract][Full Text] [Related]
35. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Srinivasan R; Gillett CE; Barnes DM; Gullick WJ Cancer Res; 2000 Mar; 60(6):1483-7. PubMed ID: 10749108 [TBL] [Abstract][Full Text] [Related]
36. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590 [TBL] [Abstract][Full Text] [Related]
37. Cripto-1 expression in uveal melanoma: an immunohistochemical study. Mallikarjuna K; Vaijayanthi P; Krishnakumar S Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323 [TBL] [Abstract][Full Text] [Related]
38. The use of monoclonal antibody immunoconjugates in cancer therapy. Pietersz GA; Krauer K; McKenzie IF Adv Exp Med Biol; 1994; 353():169-79. PubMed ID: 7985535 [No Abstract] [Full Text] [Related]
39. TDGF1 is a novel predictive marker for metachronous metastasis of colorectal cancer. Miyoshi N; Ishii H; Mimori K; Sekimoto M; Doki Y; Mori M Int J Oncol; 2010 Mar; 36(3):563-8. PubMed ID: 20126975 [TBL] [Abstract][Full Text] [Related]
40. An evaluation of different Cripto-1 antibodies and their variable results. Gudbergsson JM; Duroux M J Cell Biochem; 2020 Jan; 121(1):545-556. PubMed ID: 31310365 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]